1 Genomic characterization of invasive typhoidal and non-typhoidal Salmonella in

2 southwestern Nigeria

4	Odion O. Ikhimiukor ¹ , Anderson O. Oaikhena ¹ , Ayorinde O. Afolayan ¹ , Abayomi Fadeyi ² ,
5	Aderemi Kehinde ³ , Veronica O Ogunleye ³ , Aaron O. Aboderin ⁴ , Oyinlola O. Oduyebo ⁵ ,
6	Charles J. Elikwu ⁶ , Erkison Ewomazino Odih ¹ , Ifeoluwa Komolafe ¹ , Silvia Argimón ⁷ ,
7	Abiodun Egwuenu ⁸ , Ini Adebiyi ³ , Oluwadamiloa A. Sadare ⁶ , Tochi Okwor ⁸ , Mihir Kekre ⁷ ,
8	Anthony Underwood ⁷ , Chikwe Ihekweazu ⁸ , David M. Aanensen ⁷ and Iruka N. Okeke ¹
9	
10	
11	¹ Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance,
12	Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan,
13	Ibadan, Oyo State, Nigeria.
14	² Department of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara
15	State, Nigeria.
16	³ Department of Medical Microbiology and Parasitology, University College Hospital,
17	Ibadan, Oyo State, Nigeria.
18	⁴ Department of Medical Microbiology and Parasitology, Obafemi Awolowo University
19	Teaching Hospitals Complex, Ile-Ife, Nigeria.
20	⁵ Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences,
21	College of Medicine, University of Lagos, Lagos, Nigeria
22	⁶ Department of Medical Microbiology, School of Basic Clinical Sciences, Benjamin Carson
23	College of Health and Medical Sciences, Babcock University & Teaching Hospital, Ilishan-
24	Remo, Ogun State, Nigeria.

- 25 ⁷Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford,
- 26 Oxford, United Kingdom.
- ⁸Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

28 ABSTRACT

36

Background: Salmonellosis causes significant morbidity and mortality in Africa. Despite being endemic in Nigeria, information on circulating lineages of invasive *Salmonella* is sparse.

Methods: Salmonella enterica isolated from blood (n=60) and cerebrospinal fluid (CSF, n=3) between 2016 and 2020 from five tertiary hospitals in southwest Nigeria were antimicrobial susceptibility-tested and Illumina-sequenced. Genomes were analysed using publicly-available bioinformatic tools.

Results: Isolates and sequence types (STs) from blood were S. Typhi [ST1, n = 1 and ST2, n

37 =43] and invasive non-typhoidal Salmonella (iNTS) (S. Enteritidis [ST11, n=7], S. Durham 38 [ST10, n=2], S. Rissen [ST8756, n=2], S. Chester [ST2063, n=1], S. Dublin [ST10, n=1], S. 39 Infantis [ST603, n=1], S. Telelkebir [ST8757, n=1] and S. Typhimurium [ST313, n=1], S. 40 Typhi ST2 (n=2) and S. Adabraka ST8757 (n=1) were recovered from CSF. Most S. Typhi 41 belonged to genotype 3.1.1 (n=44), carried an IncY plasmid and had several antibiotic 42 resistance genes (ARGs) including bla_{TEM-1} (n=38), aph(6)-Id (n=32), tet(A) (n=33), sul2 43 (n=32), *dfrA14* (n=30) as well as quinolone resistance-conferring gyrA_S83Y SNPs (n=37). 44 All S. Enteritidis harboured aph(3'')-Ib, bla_{TEM-1} , catA1, dfrA7, sul1, sul2, tet(B) genes, and 45 a single ARG, qnrB19, was detected in S. Telelkebir.. Typhoidal toxins cdtB, pltA and pltB 46 were detected in S. Typhi, Rissen, Chester, and Telelkebir. 47 **Conclusion:** Most invasive salmonelloses in south west Nigeria are vaccine-preventable 48 infections due to multidrug-resistant, West African dominant Typhi lineage 3.1.1.. Invasive

49 NTS serovars, including some harbouring typhoidal toxin or resistance genes represented a

50 third of the isolates emphasizing the need for better diagnosis and surveillance.

51

53

54 Author Summary

- 55 Whole genome sequencing of 63 invasive Salmonella from 5 tertiary hospitals in Nigeria
- 56 revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring S.
- 57 Typhi 3.1.1 genotype comprising a gyrA_S83Y and IncY plasmid. We also report invasive
- 58 non-typhoidal *Salmonella* harbouring typhoidal toxins.
- 59
- 60

61 INTRODUCTION

62 Salmonella are a group of Gram negative, motile, facultative anaerobic rod-shaped bacteria 63 belonging to the *Enterobacteriaceae* family. This genus consists of two known species, 64 Salmonella enterica and Salmonella bongori. S. enterica are further distributed across six 65 subspecies, of which the S. enterica subsp. enterica are most reported in infections involving 66 homeotherm animals [1]. Furthermore, S. enterica subsp. enterica consists of over 1500 67 serovars with distinct antigenic specificity [2]. The human host-adapted S. enterica subsp. 68 enterica servars are usually associated with three marked clinical syndromes: Salmonella 69 enterica subsp. enterica servor Typhi cause typhoid fever, and the non-typhoidal Salmonella 70 (NTS) cause bacteraemia and gastroenteritis in immunocompromised (including persons with 71 advanced HIV disease, cases of severe malaria and malnutrition in children) and 72 immunocompetent persons, respectively [3,4]. S. Paratyphi A, B and C produce a syndrome 73 similar to typhoid fever.

74 The public health impact of typhoidal and invasive non-typhoidal Salmonella infections is 75 significant particularly in Africa and Asia where they have a great influence on morbidity and 76 mortality [5,6]. For instance, an estimated 17.8 million cases of typhoid fever occur each year 77 in low and middle-income countries (LMICs) [7]. An earlier estimate suggests that the 78 burden of typhoid fever is >100 per 100000 individuals per annum in sub-Saharan Africa 79 with an associated 1% mortality [8,9]. Furthermore, an estimated 26% (33,490 lives lost) of 80 the annual global typhoid-related mortality is reported to occur in Africa [9]. The disease 81 burden of typhoid in Nigeria is estimated at 364,791 typhoid cases resulting in 4,232 deaths 82 (affecting 68% of individuals under 15 years of age) as at 2016 [10], however population-83 based data are only just becoming available [11]. Globally, NTS is estimated to cause 84 approximately 94 million cases of gastroenteritis per annum worldwide with a resultant 85 mortality of 155,000 [12]. In immunocompromised cases of the disease (amongst HIV-

positive adults), NTS is reported to cause a 20% case fatality (212,000 deaths) in sub-Saharan
Africa (SSA) annually, while also being responsible for over 1 million cases of bloodstream
infections in children in SSA with a case fatality of 18.1% (197,000 child mortality)
[4,13,14].

90 Although available reports suggest infection with Salmonella enterica to be the most 91 common cause of bloodstream infections in Africa [15], the incidence and microbiology of 92 typhoidal and invasive non-typhoidal Salmonella (iNTS) is still poorly understood. Many 93 regions on the continent have garnered little or no attention in the literature [7]. Blood 94 culture-based surveillance represents the standard method for assessing the epidemiology and 95 aetiology of bacterial invasive infections [16]. Limited surveillance of invasive Salmonella on 96 the Africa continent is majorly due to financial, logistical, and infrastructural constraints for 97 the institution and maintenance of blood culture-based surveillance systems in the region 98 [7,8,16,17].

99 Such limitations not only obscure the true burden and prevalence of invasive Salmonella 100 infections in resource-limited settings but also limit opportunity for genomic surveillance of 101 this pathogen. For instance, despite the huge burden of typhoid infections in Nigeria, before 102 the current study, there were only 131 Salmonella genomes (all S. Typhi) from the country on 103 Pathogenwatch (https://pathogen.watch/, 15th November 2021) [18], a web-based platform 104 for surveillance of microbial genomes all of which were collected on or before 2013, and 105 most from only two centres [19]. Lack of genomic surveillance information of invasive 106 Salmonella in resource-limited countries, including Nigeria, may deter interventions 107 necessary to ameliorate this burden, such as the typhoid conjugate vaccines [8,17,19,20]. 108 Hence, this report provides genomic characterization of 2016-2020 invasive Salmonella 109 retrieved from tertiary hospitals enrolled into Nigeria's Antimicrobial Surveillance Network 110 coordinated by the Nigeria Centre for Disease Control (NCDC).

1	1	1
т	т	T

112

113 MATERIALS AND METHODS

114 **Ethical considerations**

Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action plan. Ethical approval for using them in research was obtained from the University of Ibadan/University College Hospital ethics committee (UI/EC/15/093). Patient consent was not obtained and the data were analysed anonymously.

119

120 Isolate collection, Identification and Antimicrobial Susceptibility Testing

121 Tertiary hospitals located in southwest Nigeria and enrolled into the Nigeria Antimicrobial 122 Surveillance Network provided cryopreserved isolates from blood and cerebrospinal fluid to 123 the AMR National reference laboratory. The isolates were from retrospectively batched 124 periods of 2016-2018 (retrospective isolates), 2019 and 2020. The national reference lab in 125 partnership with the Global Health Research Unit for the Genomic Surveillance of 126 Antimicrobial Resistance (GHRU-GSAR) conducted the re-identification of the isolates 127 using the Gram-negative (GN) test kit on (Ref: 21341) on VITEK 2 systems (version 2.0, 128 Marcy-l'Etoile, France, Biomérieux). Briefly, the cryopreserved isolates (at -80 °C) are 129 resuscitated before use for reidentification by subculturing onto Salmonella-Shigella Agar 130 and incubated aerobically at 37°C. Isolated colonies from pure cultures are the streaked on 131 Nutrient Agar (NA), incubated aerobically at 37°C. Isolated colonies on NA is then used to 132 prepare inoculum for VITEK using GN cards. This test is based on forty-seven biochemical 133 tests and a negative control. The cards contain wells with substrates for the different tests in 134 dried form. The cards are inoculated with a saline suspension of the organisms before 135 incubation. Upon incubation, biochemical reactions are read by the machine and recorded as

136 positive or negative. A bionumber which is based upon the combination of different test 137 results is then generated. The bionumber is compared to VITEK 2 robust database to match 138 the organism and this is used to identify the organism. An added step for confirming identity 139 of VITEK-identified isolates utilized whole-genome sequencing of all isolates. Antimicrobial 140 susceptibility testing was done using VITEK AST N280 test kit (Ref: 413432). N280 Cards 141 are incubated within the VITEK 2 compact upon inoculation with appropriate saline 142 suspension of test organism. The minimum inhibitory concentration (MIC) is recorded as the 143 highest concentration of an antibiotic for which no bacterial growth is observed. The MICs 144 were interpreted as either resistant, intermediate or susceptible in accordance to CLSI 145 standards [21].

146

147 **DNA extraction and Library preparation**

The isolates were processed for the extraction of genomic DNA using Wizard DNA extraction kit (Promega; Wisconsin, USA) following manufacturer's instructions. The extracted DNA was quantified on a Qubit fluorometer (Invitrogen; California, USA) using dsDNA Broad Range quantification assay. Double-stranded DNA libraries were prepared using the Covaris LC220 for fragmentation, and NEBNext Ultra II FS DNA library kit for Illumina with 384-unique indexes (New England Biolabs, Massachusetts, USA; Cat. No: E6617L). Libraries were sequenced on an Illumina HiSeq X10 (Illumina, California, USA).

155

156

157 Genome Assembly

Generated sequence reads from Illumina runs were *de novo* assembled following GHRU protocols (<u>https://gitlab.com/cgps/ghru/pipelines/ds12/pipelines/assembly</u>) using a Nextflow workflow which inclusively comprises of adapter trimming (trimmomatic v0.38),

161 contamination detection (ConFindr v0.7.2), assembly (SPAdes v3.12.0), Quality Control

162 (multiqc v1.7, qualifyr v1.4.4) and Bactinspector (v 0.1.3).

163

164 Sequence typing of Salmonella genomes

Sequence reads were deposited in the *Salmonella* database on EnteroBase [22]. Multi-locus sequence types (MLST) for the isolates were determined and core-genome MLST calculated. Evolutionary relationship based on cgMLST of all *S*. Typhi of human origin from Africa deposited in Enterobase were determined [22]. The *Salmonella* genome assemblies were analysed using the *Salmonella* In-Silico Typing Resource (SISTR) for the prediction of serovars and serogroups (https://github.com/phac-nml/sistr_cmd). Genomes belonging to *S*. Typhi were loaded unto Pathogenwatch for the prediction of their genotypes [18].

172

173 Identification of AMR, Plasmids, Virulence genes and Salmonella Pathogenicity islands

174 Determinants of AMR, virulence and plasmid replicons were identified following GHRU 175 protocols (https://gitlab.com/cgps/ghru/pipelines). Prediction of *Salmonella* pathogenicity

176 islands (SPIs) in the genomes was done by mapping raw reads to SPIs database

177 (https://bitbucket.org/genomicepidemiology/spifinder_db)

178

179 Single Nucleotide Polymorphism (SNP) calling and phylogeny

The sequence reads of the *S*. Typhi and *S*. Enteritidis genomes from our study were mapped to NCBI reference sequence, *Salmonella* enterica subsp. enterica serovar Typhi strain H12ESR00755-001A (assembly accession: GCF_001362195.2) and *Salmonella* enterica subsp. enterica serovar Enteritidis strain 18569 (assembly accession: GCF_000335875.2), respectively, to determine evolutionary relationship amongst the strains following GHRU nextflow SNP phylogeny protocols (https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny).

Briefly, reads were trimmed (trimmomatic v0.38) and mapped to the reference genomes described above using bwa mem (v0.7.17) and variants were called and filtered using bcftools (v1.9). A pseudoalignment with the reference was used to generate a maximum likelihood tree using iqtree (v1.6.8) [23]. SNP distances between the genome pairs were calculated using snp-dists v.0.8.2 (https://github.com/tseemann/snp-dists) on the pseudogenome alignment.

192

193 Availability of sequence data

Raw sequence data generated from this study are deposited in the European Nucleotide
Archive under Bioproject PRJEB29739. Accession numbers for each genome is available in
Supplementary Table 1.

197

198 RESULTS

199 Invasive Salmonella from sentinel hospitals from Nigeria's AMR Surveillance Network

Using the VITEK system for bacterial identification described above, a total of 69 isolates retrieved from patients from five (n=5) sentinel hospitals were identified as *Salmonella* spp., at the reference laboratory. However, results from whole-genome sequencing confirmed n=61 of these to be *Salmonella enterica*. In addition, two other isolates from our surveillance collection initially identified as *Escherichia coli* and *Acinetobacter baumanii* using VITEK were subsequently identified as *Salmonella enterica* using WGS.

206 The sixty-three (63) WGS-confirmed invasive Salmonella isolates have average number of

207 contigs was 58 and N50 values ranged from 172132bp to 731013bp (average 246872 bp).

208 The G+C (%) content of the genomes ranged from 51.86% - 52.37% (average 52.10%)

209 (Supplementary Table 1). The isolates were retrieved from blood (n=60) and cerebrospinal

210 fluid (n=3). The sending sentinel hospitals include: University of Ilorin Teaching Hospital

211 (ILO, Ilorin, Kwara State, n=25), University College Hospital, Ibadan (UCH, Ibadan, Oyo 212 State, n=23), Obafemi Awolowo University Teaching Hospital, Ile-Ife (OAU, Ile-Ife, Osun 213 State, n=8), Lagos University Teaching Hospital (LUT, Idi-Araba, Lagos State, n=4) and 214 Babcock University Teaching Hospital (BUT, Ilishan-Remo, Ogun State, n=3) (Fig. 1A). 215 Majority of the isolates were retrieved in 2019 from ILO (n=22). Thirteen isolates had no 216 year specified metadata but were retrospective isolates retrieved between 2016 and 2018 (Fig 217 1A). The hospitals are all in the southwestern part of Nigeria with ILO just north of the 218 South-West geopolitical zone and all the rest within it. All the Salmonella isolates from 219 cerebrospinal fluid were obtained from LUT.

220

221 Distribution of Salmonella enterica subsp. enterica serovars across sentinel hospitals

222 All the Salmonella enterica isolates belonged to the subspecies enterica but differed by

serotype with a total of 10 serovars detected. They include Typhi (n=46), Enteritidis (n=7),

224 Durham (n=2), Rissen (n=2), Adabraka (n=1), Chester (n=1), Dublin (n=1), Infantis (n=1),

225 Telelkebir (n=1), Typhimurium (n=1). Three Salmonella enterica isolates belonging to

serovars Adabraka (n=1) and Typhi (n=2) were retrieved from cerebrospinal fluid from LUT.

227 All other Salmonella serovars were retrieved by blood culture at the respective sentinel sites

228 (Supplementary Table 1). Salmonella Typhi and iNTS were recovered from all sentinel sites,

229 with iNTS being much less frequently recovered (Fig. 1B).

230 Sequence types, genotypes, and nucleotide polymorphisms.

231 Salmonella sequence-typing based on Achtman's MLST scheme [24] identified two S. Typhi

232 Sequence Types (STs) (ST1 =1 and ST2 = 45). There were nine different iNTS STs. These

- 233 included previously reported invasive STs: S Enteritidis ST11 (n=7) and S Typhimurium
- 234 ST313 (n=1), which are repeatedly reported from Africa. Other iNTS were S. Dublin (ST10),
- 235 S. Infantis (ST603), S. Durham (ST2010), S. Chester (ST2063), S. Telelkebir (ST2222). Two

novel STs belonging to *S*. Rissen and *S*. Adabraka were curated and designated STs 8756 and
8757 respectively by EnteroBase.

238 To further place our S. Typhi genomes in a wider context, we performed cgMLST analysis 239 based on differences in core genomes of our strains and all S. Typhi from human sources in 240 Africa deposited in EnteroBase (n=980) (Fig 2). All genomes included in this study had 241 similar core genome allelic differences at HC400, whereas at HC200 genomes from this 242 study had similar allelic profile with 98.06% (n=961) of the genomes in the population. 243 Genomes accounting for the difference in cluster numbers in the population at HC400 were 244 from Nigeria (n=9, ~0.92%), Cameroon (n=4, ~0.41%) Algeria (n=3, ~0.3%) Morocco (n=2, 245 0.2%) and Senegal (n=1, 0.1%). Generally, S. Typhi genomes from this study clustered with 246 others from West Africa, including Nigeria, Cameroon, Togo, Mauritania, Mali, Burkina 247 Faso, Guinea, Benin, and Ivory Coast, emphasizing further on their endemicity in the West 248 Africa region (Fig 2).

249 Further, based on S. Typhi genotyping scheme, we observed that the isolate of S. Typhi ST1 250 belonged to genotype 4.1 (UCH), whereas genotypes 2.3.1 (n=1, UCH) and 3.1.1 (n= 44) 251 were S. Typhi ST2 isolates. In addition, S. Typhi genomes from CSF (n=2) belonged to the 252 3.1.1 genotype. To further investigate the genetic relatedness of the genomes in this study, we 253 report outcome of pairwise SNP differences among the genomes. Pairwise SNP difference 254 ranged from 401 to 431 between S. Typhi 4.1 and other S. Typhi genotypes in this study, 255 whereas it was 401 to 521 between S. Typhi 2.3.1 and other S. Typhi genotypes. The 256 dominant Typhi genotype, S. Typhi 3.1.1 were 0 to 47 SNPs apart (Supplementary Table 3). 257 Among S. Enteritidis, pairwise SNP difference ranged from 0 to 44 in the three sentinel labs 258 (UCH, OAU, ILO) where they were isolated. One pair of S. Enteritidis isolates from UCH 259 were identical and the third isolate was 33 SNPs apart from them. The three S. Enteritidis

isolates from ILO (n=3) were near identical having pairwise SNP range from 0 to 1(Supplementary Table 4).

262

263 Antimicrobial susceptibility profiles, antimicrobial resistance determinants and

264 plasmids replicons in TS and NTS

265 Antimicrobial susceptibility testing revealed majority of the S. Typhi to be resistant to 266 sulphamethoxazole/trimethoprim (SXT) and ampicillin (n=41 each) and nalidixic acid 267 (n=36), of which three were ciprofloxacin non-susceptible, according to CLSI (2021) criteria. 268 (Supplementary Table 2). While not relevant to the antimicrobial chemotherapy of invasive 269 infections, resistance to nitrofurantoin was identified in the n=2 S. Typhi isolated from CSF 270 and in n=9 isolates from blood with the highest MICs (128 μ g/mL) seen in the CSF isolates 271 only. Resistance to cephalosporins, cefuroxime and cefuroxime axetil was observed in S. 272 Typhi 3.1.1 from UCH.

The single *S*. Typhi 2.3.1 isolate was resistant to ampicillin and SXT whereas no phenotypic resistance was observed with *S*. Typhi 4.1. All *S*. Enteritidis and *S*. Typhimurium were resistant to ampicillin and sulphamethoxazole/trimethoprim. Asides Telelkebir harbouring resistance to nalidixic acid and ciprofloxacin, other NTS were either susceptible or intermediately resistant to other antimicrobials (Supplementary Table 2). For example, *S*. Adabraka, Dublin and Telelkebir were intermediately resistant to cefuroxime axetil. (Supplemental Table 2 and microreact link for antimicrobial susceptibility testing:

280 <u>https://microreact.org/project/ahQ3Yb64nsbnhHMzz3WQn9-genomic-epidemiology-of-</u>

- 281 invasive-salmonella-in-southwestern-nigeria-ast-data)
- 282

283 A combined total of 14 acquired antimicrobial resistance genes (ARGs) conferring resistance

to drugs within seven antibiotic classes were detected amongst the genomes. Amongst the *S*.

285 Typhi genomes, n=36/46 harboured at least one ARG conferring reduced susceptibility to 5 286 antibiotic classes, with n=41 harbouring a sulphonamide resistance gene [sul1 = 9/46, sul2 = 287 33/46] and n=39 each harbouring a beta-lactam (*bla*_{TEM-1}), tetracyclines (*tetA*, n=33 and *tetB*, 288 n=6), and trimethoprim resistance determinant (dfrA1, [n=1], dfrA15 [n=8] and dfrA14289 [n=30]). In addition, chloramphenicol resistance genes, *catA1*, were also detected in the 290 genomes (n=8). Point mutations identified among the sequenced S. Typhi isolates were those 291 associated with the quinolone resistance determining region (QRDR), gyrA_S83Y SNPs 292 (n=37), which mediate resistance to fluoroquinolones (Fig 3). Furthermore, n=45 of the S. 293 Typhi genomes had at least one plasmid predicted to occur in each genome. Majority (n=33)294 possessed an IncY plasmid replicon, plasmid replicons IncFIA_HI1, IncHIA and IncHIB 295 were respectively detected in n=9 of S. Typhi genomes whereas one isolate harboured an 296 IncQ plasmid replicon (Fig 3).

297

298 For the iNTS, S. Enteritidis genomes possessed at least one ARG to six antibiotic classes. All 299 Isolates of this serotype harboured aph(3")-Ib, bla_{TEM-1} , catA1, dfrA7, sul1, sul2, tet(B)300 genes, and only differed in the absence/presence of aph(6)-Id (n=4) (Fig 4). In tandem, S. 301 Typhimurium harbour ARGs [aadA1, aph(3'')-Ib, aph(6)-Id, bla_{TEM-1}, catA1, dfrA1, sul1, 302 sul2] encoding resistance to 5 antibiotic classes (Fig 5). The only occurring quinolone 303 resistance gene among isolates in this study, qnrB19, was detected in S. Telelkebir. No ARGs 304 were detected in Salmonella serovars Chester, Rissen, Durham, Infantis, Adabraka and 305 Dublin. Antimicrobial point mutations identified among iNTS were associated with gyrA and 306 *parC* gene regions (Fig 5). The quinolone resistance conferring gyrA D87Y SNPs were 307 identified only amongst S. Enteritidis (ILO, n = 3 and UCH, n = 1), whereas the parC_T57S 308 mutations were detected in all iNTS except S. Enteritidis and S. Typhimurium. Plasmids

were predicted to occur only in S. Dublin [IncFII(S), IncX1 and IncX1_1], S. Enteritidis 310 (IncI1 and IncQ1), S. Typhimurium [IncFIB, IncFII(S) and IncQ1] among the iNTS.

311

309

312 Predominant IncY + gyrA_S83Y + tetA harbouring S. Typhi 3.1.1 in Nigeria

313 We observe that all S. Typhi of the 3.1.1 lineage harbouring an IncY plasmid replicon 314 (n=33/46) similarly possessed the gyrA_S83Y chromosomal gene mutation and harboured a 315 *tetA* gene. Although other antimicrobial resistance genes were seen at slightly lower numbers 316 (n = 32/33 for sul2 and aph(6)-Id and n=30/33 for bla_{TEM-1} and dfrA14), the 317 IncY+gyrA S83Y+tetA in S. Typhi 3.1.1 phenomenon was observed to occur in all the 318 sentinel hospitals in this study. Additionally, maximum pairwise SNP distance between the 319 variants in this cluster was 23. This is approximately twice as less of what was determined in 320 S. Typhi 3.1.1 outside this cluster (n=47), thereby, emphasizing clonality within this cluster.

321

322 Salmonella virulence determinants and predicted pathogenicity islands

323 The isolates possessed a plethora of virulence determinants (Supplementary Table 2). Among 324 the S. Typhi genomes, a total of 98 virulence determinants were detected, and 97 of these 325 were conserved within members of this servor (with the exception of *pipB2* gene in an S. 326 Typhi 3.1.1 from UCH).

327 A total of 106 virulence genes were detected among the S. Enteritidis genomes, 104 of these 328 were conserved within these genomes, with 2 strains from UCH lacking either a Salmonella 329 secreted protein H (sspH) or secretion system effector I (sseI). A total of 122 virulence genes 330 were detected in the iNTS genomes, and n=86 of these were conserved in all iNTS genomes. 331 For instance, the iNTS possessed genes encoding (i) Adherence; such as agf – thin 332 aggregative fimbrae or curli (csgABCDEGF), misl - an autotransporter protein, pef - plasmid-333 encoded fimbrae (present only in S. Typhimurium) ratB (carried by iNTS strains harbouring

334 CS54 islands), shdA (only found in S. Infantis), sinH (detected in all NTS except S. 335 Enteritidis) and Type 1 fimbrae (*fimCDFHI*) (ii) Stress adaptation; sodCI – superoxide 336 dismutase (detected in iNTS serovars except Durham, Chester and Rissen and Infantis and 337 Telelkebir), sopA (not detected in S. Infantis) (iii) Nutritional/metabolic factor (mgtBC, 338 present in all strains) (iii) Antimicrobial activity/competitive advantage; such as macrophage 339 inducible genes (*mig-14*, present in all strains) and (iv) Enterotoxin; T3SS effectors -spvBC340 (in S. Typhimurium, Enteritidis and Dublin), avrA (in all iNTS except S. Dublin) and 341 Typhoidal toxin - *cdtB* (present in *S*. Durham, *S*. Telelkebir and *S*. Chester).

Since the *cdtB* are reported to be co-located with other cytolethal distending toxins (*cdt*), pertussis-like toxins A (*pltA*) and B (*pltB*), on same pathogenicity islet [25], we ran a blast search of our strains for the presence of *pltA* and *pltB*. The nucleotide sequences were extracted from the virulence factor database (VFDB) and used as a local database for a blast search against our iNTS genomes. Our results reveal high similarity (100% coverage and \geq 96.62% identity) with *cdtB*, *pltA* and *pltB* genes in the iNTS genomes (*S*. Chester, *S*. Durham and *S*. Telelkebir).

349

350 Eleven and twelve Salmonella pathogenicity islands (SPIs) were predicted in S. Typhi and 351 iNTS genomes, respectively (Fig 6). All S. Typhi were predicted to have 10 SPIs, i.e., SPI-1, 352 SPI-2, SPI-3, SPI-4, SPI-5, SPI-6, SPI-7, SPI-8, SPI-9, SPI-10 and SPI-12. However, SPI-4 353 was predicted to occur only in S. Typhi lineages 2.3.1 and 4.1. In contrast to S. Typhi, only 354 SPI-3 was predicted to occur in all the iNTS genomes. Certain SPIs were shown to be 355 associated with members of certain serovars. For instance, SPI-2 and SPI-8 were detected 356 only in S. Typhimurium and S. Rissen, respectively. Other pathogenicity islands were 357 detected in this study (Fig 3), such as SPI-4 (S. Adabraka, Chester, Typhimurium), SPI-6 (all 358 NTS except S. Durham, Rissen and Telelkebir), SPI-12 (all NTS except S. Chester, Durham,

Rissen and Telelkebir) and CS54_island was detected in *S*. Dublin, *S*. Typhimurium, *S*.
Infantis and *S*. Enteritidis (n=6).

361

362 DISCUSSION

363 In this report we present the outcome of genomic characterization of invasive Salmonella 364 infections from AMR surveillance in sentinel hospitals in Nigeria. The genomic 365 characterization of invasive Salmonella isolates in this study was possible because these 366 hospitals perform blood culture and are enrolled in Nigeria's new antimicrobial resistance 367 surveillance system, which offers genomic services at the National Reference Laboratory 368 level [26]. Nonetheless, blood culture is available at very few institutions in Nigeria, a 369 limitation still prevalent in many African settings that impacts the genomic surveillance of 370 invasive Salmonella. [8,16,27]. Moreover, these sentinels perform very few blood cultures so 371 that the isolates studied here represent a very small proportion of circulating strains.

372

373 Using high-throughput WGS and bioinformatic analytics, we were able to determine 374 prevalent serotypes and dominant genotypes of invasive Salmonella infections. Most of the 375 Salmonella isolates cultured from blood were S. Typhi, as has been previously reported from 376 different parts of Nigeria, including Ibadan [28–30], even though iNTS may predominate in 377 some other African settings [3,31]. While our data are few, the predominance of Typhi at all 378 sites points to a significant burden of severe disease that could be averted if Typhoid 379 Conjugate Vaccines were deployed in Nigeria. Out of a total of 10 S. Typhi genotypes 380 recorded from Nigeria in Pathogenwatch, three were identified in this study. The S. Typhi 381 genotype 3.1.1 we report was similarly common in the Nigeria cluster on Pathogenwatch 382 (n=87/131). As in our study, this cluster possessed similar prevalence of genetic determinants 383 of beta-lactam ($bla_{\text{TEM-1}} - 83.90\%$) resistance, indicating that these determinants are well-

conserved in the genotype. However, prevalence of other AMR genetic determinants from
this lineage such as *catA1*, *sul1*, *sul2*, *dfrA14*, *dfrA15*, *tetA*, *tetB* were similar with what is
reported from this study, but at different rates.

387 This multidrug-resistance gene-encoding S. Typhi 3.1.1 is shown to be one of the broadest 388 lineages in sub-Saharan Africa and endemic in the West Africa region [19,32,33]. This S. 389 Typhi genotype is frequently reported to multidrug and ciprofloxacin resistant [29,31]. All S. 390 Typhi 3.1.1 (except one from OAU) harbouring quinolone-conferring SNPs in gyrA showed 391 phenotypic resistance to nalidixic acid. Additionally, we observed that the S. Typhi genotype 392 3.1.1 clone variants harboured an IncY + $gyrA_S83Y + tetA$ genes. The Pathogenwatch 393 database includes three S. Typhi 3.1.1 strains isolated from blood samples in 2013, in Abuja, 394 north-central capital of Nigeria with similar clonal characteristics (having same genotype, 395 plasmid replicon, chromosomal QRDR and antimicrobial resistance gene, tetA) [19]. Outside 396 Nigeria, this lineage has also been identified in the United Kingdom (accession: 397 SRR7165434, SRR5585020) [32]. Our data suggest that this resistant sub-lineage is 398 predominant in our setting and should be sought elsewhere in Nigeria and the region. In 399 addition, long read sequencing to unveil the carriage of the IncY plasmids would be 400 potentially vital to understanding the success of this lineage in Nigeria.

401

402 S. Enteritidis were the most frequently recovered iNTS in our study and sent from three 403 sentinel hospitals. This outcome contrasts with earlier reports of S. Typhimurium ST313 as a 404 predominant serotype in eastern and southern Africa, but also present across the continent, 405 including Nigeria [15,34,35], but it is concordant with more recent reports describing S. 406 Enteritidis in higher proportions in invasive infections in The Gambia [36]. Several of the S. 407 Enteritidis in our study were multidrug resistant (resistant to ampicillin, SXT, nalidixic acid). 408 This multidrug resistant clone has also been reported in bacteraemia in other parts of Africa

409 [37,38]. We observed that S. Enteritidis retrieved from different patients in ILO (in 2019) had 410 highly similar genetic features (antimicrobial resistance determinants, virulence, plasmids 411 replicons) and clustered together at 0-1 SNP distances between them. The isolates were recovered on the 27th of June, 26th of August and 28th of August 2019 and their genetic, 412 413 geographic and temporal connectedness may be indicative of a previously unrecognized 414 outbreak. Both S. Typhimurium ST313 and S. Enteritidis ST11 are dominant, human-adapted 415 clones in sub-Saharan Africa [38] and are a major cause of invasive disease, with a 416 corresponding high case-fatality rate [14]. These serovars are justifiably vaccine development 417 priorities. Non typhoidal Salmonella serovars, such as Dublin, Infantis, Chester, Rissen have 418 been reported severally from food animals [39–43], their presence in human invasive human 419 infection may attest to concerns with water and food safety, including animal contact [44– 420 46]. Although no ARGs were detected in this genome of these serovars, they remain a public 421 health concern [46,47]. The single occurrence of an acquired quinolone resistance gene, 422 qnrB19 in this study was detected in S. Telelkebir. The strain also harboured phenotypic 423 resistance to the quinolone, nalidixic acid and ciprofloxacin. S. Telelkebir has been reported a 424 few times in Africa (as seen in Enterobase, [48]), and are more commonly reported in parts of 425 Europe, China and USA [49]. The expansion of atypical Salmonella serovars in invasive 426 infections is associated with a high health burden [17,36]. Invasive NTS vaccines in the 427 pipeline may not cover all NTS serovars [50], and we identified several in this study, 428 harbouring an assortment of virulence and antimicrobial resistance determinants. This points 429 to the need for widespread and robust access to invasive Salmonella diagnostics in Nigeria to 430 elucidate on the burden and make a case for serovar vaccine priorities [17,36,49].[49][17,36] 431

432 Amongst a plethora of virulence determinants present on both *S*. Typhi and iNTS, we 433 observed that *S*. Telelkebir, *S*. Durham and *S*. Chester isolates harboured the cytolethal

434 distending toxin islet genes (*cdtB*, *pltA*, *pltB*) also known as typhoid toxin. These toxins were 435 originally thought to be restricted to serovars Typhi and Paratyphi A [51]. However, these 436 have now been reported in other NTS serovars including Bredeney, Javiana, Montevideo, 437 Schwarzengrund, and more recently in Telelkebir [52–54]. A literature search on PubMed 438 and Google Scholar revealed little information on these toxins being reported in S. Durham 439 and S. Chester. The cytolethal distending toxin islet cause DNA damage and cell cycle arrest 440 in impaired cells [55]. More implicatively, these genes encoded by NTS serovars have been 441 reported to play vital roles in disease pathogenesis [53,54]. Many of Salmonella virulence 442 determinants are clustered in pathogenicity island on the bacterial chromosome, playing key 443 roles in disease pathogenesis [56,57]. A variety of SPIs were identified in this study. The SPI-444 7 which were exclusively detected in S. Typhi in this study are known to be large and major 445 backbone constituent of S. Typhi, harbouring several virulence determinants including the Vi 446 antigen [58]. Like in this study, the CS54 island and SPI-14 island are more commonly 447 detected NTS [59–62], with scarce reports in S. Typhi, and the CS54 island are suggested to 448 have evolved over multiple horizontal transfers [63]. Thus, this study emphasizes on an 449 expanding number of serovars causing invasive infections in the country, and the public 450 health implications therein. Further studies focussed on molecular analysis of gene content of 451 SPIs in invasive Salmonella infections could be pertinent in understanding pathogenesis and 452 aid in the advancement of treatment options [64].

453

454 CONCLUSION

The outcome of our study emphasizes the need for expanded genomic surveillance of invasive *Salmonella* infections in Nigeria as a valuable tool to monitor antibiotic resistance spread and genetic characterization of circulating lineages in Nigeria. Close monitoring of the dominant *S*. Typhi 3.1.1 clone harbouring the IncY plasmid replicon and gyrA_S83Y

459 chromosomal mutation, identified in all the tertiary hospitals in this study, including other 460 serovars is vital, and this may help to establish strategies for empirical treatment and control 461 of spread of antibiotic resistant lineages. Furthermore, our data suggests that introducing 462 typhoid conjugate vaccines, recommended by the World Health Organization for countries 463 like Nigeria that have a high typhoid disease burden, will have a significant impact on health 464 [65]. Development of vaccines which target NTS would be useful in reducing the overall 465 burden of NTS on the continent. Rigorous surveillance plays an essential part in determining 466 which serovars most require coverage, as we observe S. Enteritidis to be most prevalent NTS 467 in invasive infections in southwest Nigeria, and hence recommended as vaccine priorities. 468 Importantly, broader protective effects may be achieved by improvements in water, sanitation 469 and hygiene that could interrupt transmission of the causes of typhoid and other invasive 470 salmonellosis.

471

472 FUNDING

473 This work was supported by Official Development Assistance (ODA) funding from the

474 National Institute of Health Research <u>https://www.nihr.ac.uk/</u> (grant number 16_136_111) to

475 DMA and INO and the Wellcome Trust <u>https://wellcome.org/</u> grant number 206194 to DMA.

476 INO was an African Research Leader supported by the UK Medical Research Council

477 (MRC) <u>https://mrc.ukri.org/</u> and the UK Department for International Development (DFID)

478 under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program

479 supported by the European Union (Award # MR/L00464X/1) and is presently a Calestous

480 Juma Science Leadership Fellow supported by the Bill and Melinda Gates Foundation

481 <u>https://www.gatesfoundation.org/</u> (Award # INV-036234). The funders had no role in study

482 design, data collection and analysis, decision to publish, or preparation of the manuscript.

483

484 ACKNOWLEDGEMENT

- 485 We thank Chinenye Ekemezie, Ifeoluwa J. Akintayo, Dorothy U Cyril-Okoh, Abeeb A.
- 486 Adeniyi and Ifeanyi E. Mba for excellent technical contributions and Jola-Ade J. Ajiboye for
- 487 logistic assistance. We are grateful to the administration and staff of the five sentinels for
- 488 supporting them in surveillance.
- 489
- 490
- 491
- 492
- 493
- 494

495 REFERENCES

496 1. Giner-Lamia J, Vinuesa P, Betancor L, Silva C, Bisio J, Soleto L, Chabalgoity JA, 497 Puente JL, Soncini FC, García-Vescovi E, Flores G, Pedraza J, Yim L, García C, 498 Astocondor L, Ochoa T, Hinostroza N, Graciela Pucciarelli M, Hernández-Alvarez A, 499 Del Moral V, García-Del Portillo F. Genome analysis of Salmonella enterica subsp. 500 diarizonae isolates from invasive human infections reveals enrichment of virulence-501 related functions in lineage ST1256. BMC Genomics. 2019 Jan 31;20(1):1–14. 502 2. Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, De Pinna E, Nair 503 S, Fields PI, Weill FX. Supplement 2008–2010 (no. 48) to the White–Kauffmann–Le 504 Minor scheme. Research in Microbiology. 2014 Sep 1;165(7):526-30. 505 3. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-506 typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. 507 The Lancet. 2012 Jun 30;379(9835):2489-99. 508 4. Keestra-Gounder AM, Tsolis RM, Bäumler AJ. Now you see me, now you don't: the 509 interaction of Salmonella with innate immune receptors. Nature Reviews Microbiology 510 2015 13:4. 2015 Mar 9;13(4):206–16. 511 5. Smith SI, Seriki A, Ajayi A. Typhoidal and non-typhoidal Salmonella infections in 512 Africa. Vol. 35, European Journal of Clinical Microbiology and Infectious Diseases. 513 2016. p. 1913–22. 514 Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE, 6. 515 Marks F, Thwaites GE, Van Vinh Chau N, Thompson CN, Baker S. Invasive Non-516 typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and 517 Dominant Serovars from an Infectious Disease Hospital in Vietnam. PLoS Neglected 518 Tropical Diseases. 2016 Aug 11;10(8):e0004857. 519 7. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, Marks F, 520 Pitzer VE. The burden of typhoid fever in low- and middle-income countries: A meta-

521		regression approach. PLOS Neglected Tropical Diseases. 2017 Feb
522		27;11(2):e0005376.
523 524	8.	Crump JA, Heyderman RS. A Perspective on Invasive Salmonella Disease in Africa. Clinical Infectious Diseases. 2015 Nov 1:61(suppl 4):S235–40.
525	9.	Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale V V., Ramani E, Kim YE, Park
526		JK, Wierzba TF. Burden of typhoid fever in low-income and middle-income countries:
527		a systematic, literature-based update with risk-factor adjustment. The Lancet Global
528		Health. 2014 Oct 1:2(10):e570–80.
529	10.	TvVAC. Potential of typhoid conjugate vaccines in Nigeria. 2017. 2017 Nov.
530	11.	Park SE, Toy T, Cruz Espinoza LM, Panzner U, Mogeni OD, Im J, Poudval N, Pak
531		GD. Seo H. Chon Y. Schütt-Gerowitt H. Mogasale V. Ramani E. Dev A. Park JY. Kim
532		JH. Seo HJ. Jeon HJ. Haselbeck A. Conway Roy K. MacWright W. Adu-Sarkodie Y.
533		Owusu-Dabo E. Osei I. Owusu M. Rakotozandrindrainy R. Soura AB. Kabore L.P.
534		Teferi M Okeke IN Kehinde A Popoola O Jacobs I Lunguya Metila O Meyer CG
535		Crump IA Elias S MacLennan CA Parry CM Baker S Mintz ED Breiman RF
536		Clemens ID Marks F. The Severe Typhoid Fever in Africa Program: Study Design
537		and Methodology to Assess Disease Severity Host Immunity and Carriage Associated
538		with Invasive Salmonellosis Clinical Infectious Diseases 2019 Oct
539		30:69(Supplement 6):S422–34
540	12.	Majowicz SE, Musto J, Scallan E, Angulo EJ, Kirk M, O'Brien SJ, Jones TF, Fazil A,
541		Hoekstra RM. The global burden of nontyphoidal salmonella gastroenteritis. Clinical
542		Infectious Diseases, 2010 Mar 15:50(6):882–9.
543	13.	Gordon MA. Salmonella infections in immunocompromised adults. Journal of
544		Infection. 2008 Jun 1:56(6):413–22.
545	14.	Reddy EA, Shaw A V., Crump JA. Community-acquired bloodstream infections in
546		Africa: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2010
547		Jun 1;10(6):417–32.
548	15.	Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review
549		and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections
550		among Hospitalized Patients in Africa and Asia. 2019;
551	16.	Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, Jacobs J, Hardy L.
552		Best Practices of Blood Cultures in Low- and Middle-Income Countries. Frontiers in
553		Medicine. 2019 Jun 18;6.
554	17.	Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, Rakotozandrindrainy
555		R, Baker S, Marks F. The global burden and epidemiology of invasive non-typhoidal
556		Salmonella infections. https://doi.org/101080/2164551520181504717. 2018 Jun
557		3;15(6):1421–6.
558	18.	Argimón S, Yeats CA, Goater RJ, Abudahab K, Taylor B, Underwood A, Sánchez-
559		Busó L, Wong VK, Dyson ZA, Nair S, Park SE, Marks F, Page AJ, Keane JA, Baker
560		S, Holt KE, Dougan G, Aanensen DM. A global resource for genomic predictions of
561		antimicrobial resistance and surveillance of Salmonella Typhi at pathogenwatch.
562		Nature Communications 2021 12:1 [Internet]. 2021 May 17 [cited 2021 Nov
563		13];12(1):1–12. Available from: https://www.nature.com/articles/s41467-021-23091-2
564	19.	Wong VK, Holt KE, Okoro C, Baker S, Pickard D, Marks F, Page AJ, Olanipekun G,
565		Munir H, Alter R, Fey PD, Feasey NA, Weill FX, le Hello S, Hart PJ, Kariuki S,
566		Breiman RF, Gordon MA, Heyderman RS, Jacobs J, Lunguya O, Msefula C,
567		MacLennan CA, Keddy KH, Smith AM, Onsare RS, de Pinna E, Nair S, Amos B,
568		Dougan G, Obaro S, Parkhill J, Kingsley RA, Thomson NR, Keane JA, Hawkey J,
569		Edwards DJ, Dyson ZA, Harris SR, Cain AK, Hadfield J, Klemm EJ, Watson CH,
570		John Edmunds W, Chabalgoity JA, Kama M, Jenkins K, Dutta S, Campos J,

571		Thompson C. Dolecek C. Parry CM. Karkey A. Kim Mulholland E. Campbell JI.
572		Dongol S. Basnyat B. Ariyal A. Dufour M. Bandaranayake D. Toleafoa TN. Pravin
573		Singh S, Hatta M, Isaja L, Thwaites G, Turner P, Soeng S, Crump JA, Nille EJ, Thanh
574		DP. Valcanis M. Powling J. Dimovski K. Hogg G. Connor TR. Dave J. Murphy N.
575		Holliman R. Sefton A. Millar M. Farrar J. Mather AE. Molecular Surveillance
576		Identifies Multiple Transmissions of Typhoid in West Africa PLoS Negl Trop Dis
577		[Internet] 2016 Sep 22 [cited 2022 May 2]:10(9) Available from:
578		https://pubmed.ncbi.nlm.nih.gov/27657909/
579	20	Carey ME Steele AD The Severe Typhoid Fever in Africa Program Highlights the
580	20.	Need for Broad Deployment of Typhoid Conjugate Vaccines Clinical Infectious
581		Diseases 2019 Oct 30:69(Supplement 6):S413-6
582	21	Clinical and Laboratory Standards Institute (CLSI) Performance Standards for
583	21.	Antimicrobial Susceptibility Testing 2021 31st ed CLSI supplement M100
584	22	Zhou Z Alikhan NE Mohamed K Fan Y Group the AS Achtman M Brown D
585	22.	Chattaway M Dallman T Delahay R Kornschoher C Pietzka A Malorny B
586		Petrovska I Davies R Robertson A Type W Weill FX Accou-Demartin M
587		Williams N The EnteroBase user's guide with case studies on Salmonella
588		transmissions. Versinia pestis phylogeny, and Escherichia core genomic diversity
580		Genome Research [Internet] 2020 Jan 1 [cited 2021 Nov 13]:30(1):138–52 Available
590		from: https://genome.cshlp.org/content/30/1/138 full
591	23	Nouven I T Schmidt HA von Haeseler A Minh BO IO-TREE: A Fast and Effective
592	23.	Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies Molecular
593		Biology and Evolution [Internet] 2015 Jan 1 [cited 2022 Apr 30]:32(1):268-74
50/		Available from: https://academic.oup.com/mbe/article/32/1/268/2025502
595	24	Achtman M Wain I Weill FX Nair S Zhou Z Sangal V Krauland MG Hale II
596	27.	Harbottle H. Uesbeck A. Dougan G. Harrison I.H. Brisse S. Multilocus Sequence
597		Typing as a Replacement for Serotyping in Salmonella enterica. PLOS Pathogens
598		2012.8(6):e1002776
599	25	Simon NC Aktories K Barbieri IT Novel bacterial ADP-ribosylating toxins: structure
600	20.	and function Nat Rev Microbiol [Internet] 2014 [cited 2021 Nov 20]:12(9):599
601		Available from: /nmc/articles/PMC5846498/
602	26	Afolayan AO Oaikhena AO Aboderin AO Olabisi OF Amunitan AA Abiri O y
603	20.	Ogunleve VO Odih EE Adevemo AT Adevemo AT Obadare TO Abrudan M
604		Argimón S David S Kekre M Underwood A Fgwuenu A Ibekweazu C Aanensen
605		DM Okeke IN Abudahab K Harste H Muddyman D Taylor B Wheeler N Donado-
606		Godov P. Fabian Bernal I. Arevalo A. Fernanda Valencia M. Osma Castro ECD
607		Ravikumar KI, Nagaraj G, Shamanna V, Govindan V, Prabhu A, Sravani D, Shiney
608		MR Rose S Ravishankar KN Ajihove II Carlos C Lagrada ML Macaranas PK v
609		Olorosa AM Gaveta IM Herrera FM Mollov A Stelling I Vegvari C Clones and
610		Clusters of Antimicrobial-Resistant Klebsiella From Southwestern Nigeria Clinical
611		Infectious Diseases 2021:73(Supplement 4):S308–15
612	27	Petti CA Polage CR Ouinn TC Ronald AR Sande MA Laboratory medicine in
613	27.	Africa: A harrier to effective health care. Clinical Infectious Diseases 2006 Feb
614		1·4?(3)·377–82
615	28	Obaro SK Hassan-Hanga F Olateiu EK Umoru D Lawson L Olaninekun G Ibrahim
616	20.	S. Munir H. Ihesiolor G. Maduekwe A. Ohiaeri C. Adetola A. Shetima D. Jibir BW
C10		
617		Nakaura H. Kocmich N. Aiose T. Idiong D. Masokano K. Ifabivi A. Ihebuzor N. Chen
617 618		Nakaura H, Kocmich N, Ajose T, Idiong D, Masokano K, Ifabiyi A, Ihebuzor N, Chen B, Meza J, Akindele A, Rezac-Elgohary A, Olaosebikan R, Suwaid S, Gambo M, Alter

620		Northwest Nigeria, 2008–2015. Clinical Infectious Diseases. 2015 Nov
621		1;61(suppl_4):S325–31.
622	29.	Popoola O, Kehinde A, Ogunleye V, Adewusi OJ, Toy T, Mogeni OD, Aroyewun EO,
623		Agbi S, Adekanmbi O, Adepoju A, Muyibi S, Adebiyi I, Elaturoti OO, Nwimo C,
624		Adeoti H, Omotosho T, Akinlabi OC, Adegoke PA, Adeyanju OA, Panzner U, Baker
625		S, Park SE, Marks F, Okeke IN. Bacteremia Among Febrile Patients Attending
626		Selected Healthcare Facilities in Ibadan, Nigeria, Clinical Infectious Diseases, 2019
627		Oct 30:69(Supplement 6):S466–73.
628	30.	Akinyemi KO, Ajoseh SO, Fakorede CO, A systemic review of literatures on human
629		Salmonella enterica serovars in Nigeria (1999-2018). The Journal of Infection in
630		Developing Countries [Internet] 2021 Sep 30 [cited 2022 May 19]:15(09):1222–35
631		Available from: https://idc.org/index.php/iournal/article/view/12186
632	31	Ao TT Feasey NA Gordon MA Keddy KH Angulo FI Crump IA Global burden of
633	51.	invasive nontyphoidal Salmonalla disease 2010(1) Emerg Infact Dis 2015 Jun
634		1.21(6).0/1 0
635	37	Dark SE Dham DT Boinatt C Wong VK Dak CD Danznar II Espinoza IMC von
626	32.	Kalakrauth V. Im I. Sahütt Caravitt H. Crump IA. Proiman DE. Adu Sarkadia V.
627		Nauxu Daho E. Dakotozon drindroiny D. Soura AD. Acoffa A. Cosmologod N. Koddy
629		Wusu-Dabo E, Kakolozanufindraniy K, Soura AB, Aseria A, Gasmeiseeu N, Keddy
030		Charle D. Fields D. Semens N. Desefindrahe TH. Deminesses TM. Kehers I.D. Semen
640		Chack B, Fleids B, Sarpong N, Razannurade IJL, Rannnosoa IM, Rabore LP, Sampo
04U		E, Telen M, Yeshileia B, ei Tayeo MA, Sooka A, Meyer CG, Krunkamp R, Dekker
641		DM, Jaeger A, Poppert S, Tall A, Niang A, Bjerregaard-Andersen M, Lølberg SV, Seo
642		HJ, Jeon HJ, Deerin JF, Park J, Konings F, Ali M, Clemens JD, Hugnes P, Sendagala
643		JN, Vudriko I, Downing R, Ikumapayi UN, Mackenzie GA, Obaro S, Argimon S,
644		Aanensen DM, Page A, Keane JA, Duchene S, Dyson Z, Holt KE, Dougan G, Marks
645		F, Baker S. The phylogeography and incidence of multi-drug resistant typhoid fever in
646		sub-Saharan Africa. Nature Communications [Internet]. 2018 Dec 1 [cited 2021 Nov
647		24];9(1). Available from: /pmc/articles/PMC6269545/
648	33.	Ingle DJ, Nair S, Hartman H, Ashton PM, Dyson ZA, Day M, Freedman J, Chattaway
649		MA, Holt KE, Dallman TJ. Informal genomic surveillance of regional distribution of
650		Salmonella Typhi genotypes and antimicrobial resistance via returning travellers.
651		PLOS Neglected Tropical Diseases [Internet]. 2019 [cited 2021 Nov
652		25];13(9):e0007620. Available from:
653		https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007620
654	34.	Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D,
655		Clarke L, Whitehead S, Sangal V, Marsh K, Achtman M, Molyneux ME, Cormican M,
656		Parkhill J, MacLennan CA, Heyderman RS, Dougan G. Epidemic multiple drug
657		resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa
658		have a distinct genotype. Genome Research. 2009 Dec 1;19(12):2279-87.
659	35.	Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN,
660		Kariuki S, Msefula CL, Gordon MA, De Pinna E, Wain J, Heyderman RS, Obaro S,
661		Alonso PL, Mandomando I, MacLennan CA, Tapia MD, Levine MM, Tennant SM,
662		Parkhill J, Dougan G. Intracontinental spread of human invasive Salmonella
663		Typhimurium pathovariants in sub-Saharan Africa. Nature Genetics 2012 44:11. 2012
664		Sep 30;44(11):1215–21.
665	36.	Kanteh A, Sesay AK, Alikhan NF, Ikumapayi UN, Salaudeen R, Manneh J, Olatunji
666		Y, Page AJ, Mackenzie G. Invasive atypical non-typhoidal Salmonella serovars in The
667		Gambia. Microbial Genomics [Internet]. 2021 Nov 23 [cited 2021 Nov
668		24];7(11):000677. Available from:
669		https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000677

670	37.	Akullian A, Montgomery JM, John-Stewart G, Miller SI, Hayden HS, Radey MC,
671		Hager KR, Verani JR, Ochieng JB, Juma J, Katieno J, Fields B, Bigogo G, Audi A,
672		Walson J. Multi-drug resistant non-typhoidal Salmonella associated with invasive
673		disease in western Kenya. PLOS Neglected Tropical Diseases [Internet]. 2018 Jan 1
674		[cited 2022 May 19];12(1):e0006156. Available from:
675		https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006156
676	38.	Park SE, Pham DT, Pak GD, Panzner U, Espinoza LMC, Kalckreuth V von, Im J,
677		Mogeni OD, Schütt-Gerowitt H, Crump JA, Breiman RF, Adu-Sarkodie Y, Owusu-
678		Dabo E, Rakotozandrindrainy R, Soura AB, Aseffa A, Gasmelseed N, Sooka A, Keddy
679		KH, May J, Aaby P, Biggs HM, Hertz JT, Montgomery JM, Cosmas L, Olack B,
680		Fields B, Sarpong N, Razafindrabe TJL, Raminosoa TM, Kabore LP, Sampo E, Teferi
681		M, Yeshitela B, Tayeb MA el, Krumkamp R, Dekker DM, Jaeger A, Tall A, Gassama
682		A, Niang A, Bjerregaard-Andersen M, Løfberg SV, Deerin JF, Park JK, Konings F,
683		Carey ME, Puyvelde S van, Ali M, Clemens J, Dougan G, Baker S, Marks F. The
684		genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in
685		selected sub-Saharan African countries. BMJ Global Health [Internet]. 2021 Aug 1
686		[cited 2021 Nov 1];6(8):e005659. Available from:
687		https://gh.bmj.com/content/6/8/e005659
688	39.	Gelaw AK, Nthaba P, Matle I. Detection of Salmonella from animal sources in South
689		Africa between 2007 and 2014. J S Afr Vet Assoc. 2018 Nov 7;89.
690	40.	Kidanemariam A, Engelbrecht M, Picard J. Retrospective study on the incidence of
691		Salmonella isolations in animals in South Africa, 1996 to 2006. J S Afr Vet Assoc
692		[Internet]. 2010 [cited 2022 May 3];81(1):37–44. Available from:
693		https://journals.co.za/doi/epdf/10.10520/EJC99859
694	41.	Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-
695		typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.
696		The Lancet. 2012 Jun 30;379(9835):2489–99.
697	42.	Pornsukarom S, Patchanee P, Erdman M, Cray PF, Wittum T, Lee J, Gebreyes WA.
698		Comparative Phenotypic and Genotypic Analyses of Salmonella Rissen that
699		Originated from Food Animals in Thailand and United States. Zoonoses and Public
700		Health [Internet]. 2015 Mar 1 [cited 2022 May 3];62(2):151–8. Available from:
701		https://onlinelibrary.wiley.com/doi/full/10.1111/zph.12144
702	43.	Xu X, Biswas S, Gu G, Elbediwi M, Li Y, Yue M. Characterization of Multidrug
703		Resistance Patterns of Emerging Salmonella enterica Serovar Rissen along the Food
704		Chain in China. Antibiotics 2020, Vol 9, Page 660 [Internet]. 2020 Sep 30 [cited 2022
705		May 3];9(10):660. Available from: https://www.mdpi.com/2079-6382/9/10/660/htm
706	44.	Hoelzer K, Switt AIM, Wiedmann M. Animal contact as a source of human non-
707		typhoidal salmonellosis. Veterinary Research [Internet]. 2011 Feb 14 [cited 2022 May
708		3];42(1):1–28. Available from:
709		https://veterinaryresearch.biomedcentral.com/articles/10.1186/1297-9716-42-34
710	45.	Post AS, Diallo SN, Guiraud I, Lompo P, Tahita MC, Maltha J, van Puyvelde S,
711		Mattheus W, Ley B, Thriemer K, Rouamba E, Derra K, Deborggraeve S, Tinto H,
712		Jacobs J. Supporting evidence for a human reservoir of invasive non-Typhoidal
713		Salmonella from household samples in Burkina Faso. PLOS Neglected Tropical
714		Diseases [Internet]. 2019 [cited 2022 May 3];13(10):e0007782. Available from:
715		https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007782
716	46.	Aoki Y, Watanabe Y, Kitazawa K, Ando N, Hirai S, Yokoyama E. Emergence of
717		Salmonella enterica subsp. enterica serovar Chester in a rural area of Japan. Public
718		Health J Vet Med Sci [Internet]. 2020 [cited 2022 May 3];82(5):580-4. Available
719		from: https://www.ncbi.nlm.nih.gov/pmc/journals/2350/

720 721	47.	Reddy EA, Shaw A v., Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2010
722		In 1.10(6).417–32
723	48	Harrois D Breurec S Seck A Delauné A le Hello S Pardos de la Gándara M Sontag
723	40.	I Perrier-Gros-Claude ID Sire IM Garin B Weill FX Prevalence and
725		characterization of extended spectrum B-lactamase-producing clinical Salmonella
725		entarics isolates in Dakar. Sanagal from 1000 to 2000. Clinical Microbiology and
720		Infection 2014 Feb 1.20(2):0109-16
727	19	Oiu VE Namhiar RB Xu X hin Weng ST Pan H Zheng KC Yue M Global
720	ч <i>)</i> .	Genomic Characterization of Salmonella enterica Serovar Telelkehir Frontiers in
72)		Microbiology 2021 Jul 29:12:2007
731	50	Sokaribo AS Perera SR Sereggela 7 Krochak R Balezantis I.R. Xing X I am S
731	50.	Deck W Attah Doku S Abbott DW Tamuly S White AP A GMMA CPS Based
732		Vaccine for Non Typhoidal Salmonalla, Vaccines 2021, Vol 0, Page 165 [Internet]
733		2021 Feb 17 [cited 2022 Apr 20]:0(2):165 Available from:
734		2021 Feb 17 [Clicu 2022 Api 29], $7(2)$.105. Available from:
735	51	Tamamura V. Tanaka K. Uahida I. Characterization of partussis like toxin from
730	51.	Salmonalla ann that astalyzas ADD ribosylation of C protains. Scientific Paperts 2017
121		7.1 2017 Jun 1.7(1):1 12
730	52	1.1. 2017 Juli 1,7(1).1-13.
739	52.	L Hoalzer K Podriguez Divers LD Brown S Bolchacova E Eurtado MP Wiedmann
740		L, Hoeizer K, Kounguez-Kivera ED, Brown S, Bolchacova E, Fundado Ivik, wiedmanni M. Conome acquencing reveals diversification of virulence factor content and possible
741		host adaptation in distinct subnonulations of Salmonalla antariaa DMC Canomias
742		nost adaptation in distinct subpopulations of Samonena enterica. BWC denomics. 2011 Dec $22(1)(1)(1)(1)$
745	52	2011 Dec 22,12(1):1-11. Maral EH, Baa D, Khan AA, Datastion and functionality of the CdtP. DltA, and DltP.
744	55.	from Salmonalla enterios serouar Javiana, Dethogens and Disasse, 2014 Nov
743 746		1;72(2):95–103.
747	54.	Rodriguez-Rivera LD, Bowen BM, Den Bakker HC, Duhamel GE, Wiedmann M.
748		Characterization of the cytolethal distending toxin (typhoid toxin) in non-typhoidal
749		Salmonella serovars. Gut Pathogens. 2015 Jul 24;7(1):1–7.
750	55.	Chang SJ, Jin SC, Jiao X, Galan JE. Unique features in the intracellular transport of
751		typhoid toxin revealed by a genome-wide screen. PLOS Pathogens.
752		2019;15(4):e1007704.
753	56.	Marcus SL, Brumell JH, Pfeifer CG, Finlay BB. Salmonella pathogenicity islands: big
754		virulence in small packages. Microbes and Infection. 2000 Feb 1;2(2):145–56.
755	57.	Hensel M. Evolution of pathogenicity islands of Salmonella enterica. International
756		Journal of Medical Microbiology. 2004 Sep 24;294(2-3):95-102.
757	58.	Seth-Smith HMB. SPI-7: Salmonella's Vi-Encoding Pathogenicity Island. The Journal
758		of Infection in Developing Countries [Internet]. 2008 Aug 1 [cited 2022 May
759		4];2(04):267–71. Available from: https://jidc.org/index.php/journal/article/view/220
760	59.	Shah DH, Lee MJ, Park JH, Lee JH, Eo SK, Kwon JT, Chae JS. Identification of
761		Salmonella gallinarum virulence genes in a chicken infection model using PCR-based
762		signature-tagged mutagenesis. Microbiology (N Y) [Internet]. 2005 Dec 1 [cited 2022
763		May 4];151(12):3957–68. Available from:
764		https://www.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.28126-0
765	60.	Webber B, Borges KA, Furian TQ, Rizzo NN, Tondo EC, dos Santos LR, Rodrigues
766		LB, do Nascimento VP. Detection of virulence genes in Salmonella Heidelberg
767		isolated from chicken carcasses. Revista do Instituto de Medicina Tropical de São
768		Paulo [Internet]. 2019 Jul 22 [cited 2022 May 4];61. Available from:
769		http://www.scielo.br/j/rimtsp/a/6QcGt7kdBnqKGxbyBxXTjtn/?lang=en&format=html

- 770 61. Panzenhagen PHN, Cabral CC, Suffys PN, Franco RM, Rodrigues DP, Conte-Junior 771 CA. Comparative genome analysis and characterization of the Salmonella 772 Typhimurium strain CCRJ 26 isolated from swine carcasses using whole-genome 773 sequencing approach. Letters in Applied Microbiology [Internet]. 2018 Apr 1 [cited 774 2022 May 4];66(4):352–9. Available from: 775 https://onlinelibrary.wiley.com/doi/full/10.1111/lam.12859 776 Cherchame E, Guillier L, Lailler R, Vignaud ML, Jourdan-Da Silva N, le Hello S, 62. 777 Weill FX, Cadel-Six S. Salmonella enterica subsp. enterica Welikade: guideline for 778 phylogenetic analysis of serovars rarely involved in foodborne outbreaks. BMC 779 Genomics [Internet]. 2022 Dec 1 [cited 2022 May 4];23(1):1–13. Available from: 780 https://link.springer.com/articles/10.1186/s12864-022-08439-2 781 63. Kingsley RA, Humphries AD, Weening EH, de Zoete MR, Winter S, 782 Papaconstantinopoulou A, Dougan G, Bäumler AJ. Molecular and phenotypic analysis 783 of the CS54 island of Salmonella enterica serotype Typhimurium: Identification of 784 intestinal colonization and persistence determinants. Infection and Immunity [Internet]. 785 2003 Feb 1 [cited 2022 May 4];71(2):629–40. Available from: 786 https://journals.asm.org/doi/full/10.1128/IAI.71.2.629-640.2003 787 64. Kombade S, Kaur N. Pathogenicity Island in Salmonella. Salmonella spp -788 A Global Challenge [Internet]. 2021 Mar 11 [cited 2022 May 4]; Available from: 789 https://www.intechopen.com/chapters/75674 790 65. WHO. WHO recommends use of first typhoid conjugate vaccine [Internet]. 2018 791 [cited 2021 Nov 26]. Available from: https://www.who.int/news/item/03-04-2018-792 who-recommends-use-of-first-typhoid-conjugate-vaccine 793 794
- 795

797 Figure Legends

Fig 1: Epidemiological information showing: (A) number of Salmonella isolated received from the different sentinel hospitals at different years, and (B) Number of different *Salmonella* serotypes received from the different sentinel hospitals.

801

- 802 Fig 2: Grape tree showing core genome MLST of S. Typhi from human sources in Africa,
- 803 deposited in the EnteroBase database. Red leaf labels are genomes from this study

804

- 805 Fig 3: SNP-phylogeny based tree and gene presence/absence showing the genomic profile of
- 806 Salmonella Typhi genomes retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic
- 807 resistance genes, STs: Sequence types

808

- 809 Fig 4: SNP-phylogeny based tree and gene presence/absence map showing the genomic
- 810 profile of *Salmonella* Enteritidis retrieved from 3 sentinel laboratories in Nigeria. ARGs:
- 811 antibiotic resistance genes, STs: Sequence types.

812

813 Fig 5. Gene presence/absence map showing the genomic profile of non-typhoidal Salmonella

814 retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic resistance genes, STs:

- 815 Sequence types
- 816
- Fig 6: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal
 Salmonella) and NTS (Non-typhoidal Salmonella) in this study.















